OmniAb (OABI) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed REGENXBIO (RGNX) over the past year, gaining 166.3% versus a loss of 33.8%. Over five years, OABI leads with a -53.3% price change compared with -77.5% for RGNX. OmniAb is the larger company by market cap ($703.0 million vs $541.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OABI | RGNX |
|---|---|---|
| Share price | $4.84 | $8.20 |
| Market cap | $702.96M | $541.31M |
| 1-day change | +3.76% | +1.36% |
| YTD return | +151.89% | -43.82% |
| 1-year return | +166.29% | -33.80% |
| 5-year return | -53.26% | -77.50% |
| EPS (TTM) | $-0.36 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.43 | $16.19 |
| 52-week low | $1.30 | $5.46 |
| Distance from 52-week high | -10.96% | -49.35% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +72.29% | +187.56% |
| Average volume | 1.47M | 1.53M |
| Shares outstanding | 145.39M | 66.01M |
| Employees | 89 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed RGNX by 200.1 percentage points over the past year.
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
OABI vs RGNX FAQ
Which is bigger, OmniAb or REGENXBIO?
OmniAb (OABI) is larger, with a market capitalization of $702.96M compared with $541.31M for REGENXBIO (RGNX).
Which stock has performed better over the past year, OABI or RGNX?
OABI returned +166.29% over the past 12 months, compared with -33.80% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are OmniAb and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for OmniAb and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.